3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neuroblastoma
9
Melanoma
4
Ganglioneuroblastoma
4
Triple Negative Breast Neoplasms
3
Lung Neoplasms
3
Carcinoma, Non-Small-Cell Lung
2
Adenoma, Islet Cell
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Transplant-Related Hematologic Malignancy
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Alveolar Soft Part
1
Recurrence
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma
1
Locally Advanced Pancreatic Adenocarcinoma
1
Leukemia, Plasma Cell
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Hodgkin Disease
1
Gliosarcoma
1
Glioblastoma
1
Endometrial Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Interventions
trametinib
5
dabrafenib
5
pembrolizumab
3
lenvatinib
3
cobimetinib
2
cemiplimab
2
atezolizumab
2
Vemurafenib
2
Radiotherapy, Intensity-Modulated
2
Paclitaxel
2
Nivolumab
2
zimberelimab
1
selpercatinib
1
fludarabine
1
cabozantinib
1
aldesleukin
1
abemaciclib
1
Taxes
1
Ipilimumab
1
Immunoglobulin G
1
Disulfides
1
Cyclophosphamide
1
CTLA-4 Antigen
1
Bevacizumab
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Thyroid Carcinoma, Anaplastic
×
sargramostim
×
1 year
×
Clear all
No trials found.